GERN:NGS-Geron Corporation (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 4.51

Change

0.00 (0.00)%

Market Cap

USD 0.34B

Volume

9.30M

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Geron Corp is a biopharmaceutical company that supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing GERN

CNCR Loncar Cancer Immunothera.. 3.46 % 0.79 %

-0.20 (0%)

USD 0.01B
WDNA:LSE WisdomTree BioRevolution .. 2.73 % 0.00 %

+0.33 (+0%)

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.70 % 0.00 %

+0.31 (+0%)

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.62 % 0.00 %

+29.20 (+0%)

USD 3.72M
WDNA 2.46 % 0.00 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+0.26 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 113.74% 92% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.74% 92% A 96% N/A
Trailing 12 Months  
Capital Gain 104.07% 88% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.07% 88% B+ 95% A
Trailing 5 Years  
Capital Gain 196.71% 88% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 196.71% 88% B+ 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 29.13% 76% C+ 83% B
Dividend Return 29.13% 76% C+ 83% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.13% 57% F 32% F
Risk Adjusted Return 51.89% 95% A 80% B-
Market Capitalization 0.34B 91% A- 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 8.86 15% 13%
Price / Cash Flow Ratio -16.27 88% 88%
Price/Free Cash Flow Ratio -9.06 89% 88%
Management Effectiveness  
Return on Equity -72.56% 52% 25%
Return on Invested Capital -84.13% 35% 13%
Return on Assets -32.87% 48% 16%
Debt to Equity Ratio 14.14% 51% 68%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector